{
  "docId": "019de072-4729-7396-8f8e-eb3955e66e61",
  "docSlug": "7286daabf487d40c2a70ede12061c49a",
  "documentTitle": "Apexigen | SPAC Presentation Deck | 28 slides",
  "authorId": "apexigen",
  "authorName": "Apexigen",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 28,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-4729-7396-8f8e-eb3955e66e61/11",
  "deckHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61",
  "deckJsonHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61.json",
  "deckAnchorHref": "/decks/019de072-4729-7396-8f8e-eb3955e66e61#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.25,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "image",
      "text": "Antibody structure diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ff0004c-286e-4670-930e-a82788d32c8a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.35,
        "y": 0.6
      },
      "kind": "list",
      "text": "Fc Mutation: Better Potency without ADCC; Increased agonistic potency via binding to FcyIIbR; Eliminated ADCC effector functions via abolishing binding to FcyIIIaR",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b12e362-5f19-43a5-b63c-8f1c6f4e8b64",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.2,
        "x": 0.78,
        "y": 0.25
      },
      "kind": "list",
      "text": "Single-agent efficacy; Synergy with chemoradiation, chemotherapy & anti-PD-1; Very good tolerability profile; Patent exclusivity through 2032+",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad61ab9c-0863-47cb-a0f3-d9cc9176c3ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.35,
        "y": 0.3
      },
      "kind": "list",
      "text": "High Binding Affinity to CD40 Ligand Binding Domain (Kd = 1.2x10-10M); Humanized IgG1/k mAb against human CD40; Binds to CD40L binding domain, mimicking natural CD40L signaling and increasing potency",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b397c7e9-98f9-45cc-8826-06c71db65e17",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Sotigalimab - Potentially First-in-Class and Best-in-Class CD40 Agonist Antibody",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9862ff30-dd6e-41d9-a4cd-90336abe4423",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "85f271fd-4d0a-487d-9cf4-6cd1297ed80f",
      "evidence": "The slide presents information in a list/bullet format, highlighting key features of Sotigalimab.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 11,
      "from": 10,
      "beatId": "cf2ade2d-f00f-40fa-8a0f-9569a750612a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The deck presents Sotigalimab as a potential first-in-class CD40 agonist antibody and describes the APXiMAB platform.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 15,
      "from": 10,
      "beatId": "eabcce46-c7fe-4e05-b519-ae0aa88c80cb",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The deck provides details on Sotigalimab's clinical development program and potential applications.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 10,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "3eb55c6a-aa43-4de6-9bf7-e2573f2f45ff",
      "evidence": "The deck describes Sotigalimab's mechanism of action and potential advantages.",
      "position": 1,
      "objective": "Explain how Sotigalimab works and its potential benefits",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}